Titre : Oxygénation hyperbare

Oxygénation hyperbare : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Oxygénation hyperbare : Questions médicales les plus fréquentes", "headline": "Oxygénation hyperbare : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Oxygénation hyperbare : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-26", "dateModified": "2025-04-20", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Oxygénation hyperbare" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Oxygénothérapie", "url": "https://questionsmedicales.fr/mesh/D010102", "about": { "@type": "MedicalCondition", "name": "Oxygénothérapie", "code": { "@type": "MedicalCode", "code": "D010102", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E02.880.690" } } }, "about": { "@type": "MedicalCondition", "name": "Oxygénation hyperbare", "alternateName": "Hyperbaric Oxygenation", "code": { "@type": "MedicalCode", "code": "D006931", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Richard E Moon", "url": "https://questionsmedicales.fr/author/Richard%20E%20Moon", "affiliation": { "@type": "Organization", "name": "Departments of Anesthesiology and Medicine, Center for Hyperbaric Medicine and Environmental Physiology, Duke University, North Carolina U.S." } }, { "@type": "Person", "name": "John P Kirby", "url": "https://questionsmedicales.fr/author/John%20P%20Kirby", "affiliation": { "@type": "Organization", "name": "John P. Kirby MD, FACS, is the Director of Wound Healing Programs, Associate Professor of Surgery, Section of Acute and Critical Care Surgery, at Washington University School of Medicine, Barnes-Jewish Hospital, in St. Louis, Missouri." } }, { "@type": "Person", "name": "Stephen R Thom", "url": "https://questionsmedicales.fr/author/Stephen%20R%20Thom", "affiliation": { "@type": "Organization", "name": "Emergency Medicine, University of Maryland, Baltimore, MD, USA." } }, { "@type": "Person", "name": "Michael H Bennett", "url": "https://questionsmedicales.fr/author/Michael%20H%20Bennett", "affiliation": { "@type": "Organization", "name": "Department of Diving and Hyperbaric Medicine, Prince of Wales Hospital and University of New South Wales, Sydney, New South Wales, Australia." } }, { "@type": "Person", "name": "Simon J Mitchell", "url": "https://questionsmedicales.fr/author/Simon%20J%20Mitchell", "affiliation": { "@type": "Organization", "name": "Department of Anaesthesiology, University of Auckland Faculty of Medicine, Auckland, New Zealand." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "CD69-oxLDL ligand engagement induces Programmed Cell Death 1 (PD-1) expression in human CD4 + T lymphocytes.", "datePublished": "2022-08-05", "url": "https://questionsmedicales.fr/article/35930205", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00018-022-04481-1" } }, { "@type": "ScholarlyArticle", "name": "The significance of the microlymphangiogenesis, microangiogenesis, and combined detection of programmed cell death-1 protein (PD-1)/ki67 in gastric cancer tissues.", "datePublished": "2023-05-13", "url": "https://questionsmedicales.fr/article/37179266", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00432-023-04709-y" } }, { "@type": "ScholarlyArticle", "name": "Are programmed cell death protein-1 and Angiopoietins-2 effective biomarkers for detection the severity of psoriatic patients?", "datePublished": "2022-05-25", "url": "https://questionsmedicales.fr/article/35506216", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jocd.15039" } }, { "@type": "ScholarlyArticle", "name": "The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1", "datePublished": "2022-07-22", "url": "https://questionsmedicales.fr/article/35935985", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.830606" } }, { "@type": "ScholarlyArticle", "name": "Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment.", "datePublished": "2023-02-17", "url": "https://questionsmedicales.fr/article/36801909", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-29971-5" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Thérapeutique", "item": "https://questionsmedicales.fr/mesh/D013812" }, { "@type": "ListItem", "position": 3, "name": "Thérapie respiratoire", "item": "https://questionsmedicales.fr/mesh/D012138" }, { "@type": "ListItem", "position": 4, "name": "Oxygénothérapie", "item": "https://questionsmedicales.fr/mesh/D010102" }, { "@type": "ListItem", "position": 5, "name": "Oxygénation hyperbare", "item": "https://questionsmedicales.fr/mesh/D006931" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Oxygénation hyperbare - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Oxygénation hyperbare", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Oxygénation hyperbare", "description": "Comment diagnostiquer une décompression ?\nQuels tests pour l'oxygénation hyperbare ?\nQuels symptômes indiquent un traitement ?\nComment évaluer l'efficacité du traitement ?\nQuels critères pour l'admission en chambre hyperbare ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Oxygénation hyperbare", "description": "Quels sont les symptômes de l'oxygénation hyperbare ?\nComment se manifeste l'intoxication à l'oxygène ?\nQuels signes d'une embolie gazeuse ?\nQuels symptômes après une séance d'oxygénation ?\nComment reconnaître une réaction allergique ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Oxygénation hyperbare", "description": "Comment prévenir la maladie de décompression ?\nQuelles précautions avant une séance ?\nComment éviter l'intoxication à l'oxygène ?\nQuelles sont les recommandations post-traitement ?\nComment se préparer psychologiquement ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Oxygénation hyperbare", "description": "Quelles conditions traitent l'oxygénation hyperbare ?\nComment se déroule une séance d'oxygénation ?\nQuelle est la durée d'une séance ?\nY a-t-il des effets secondaires ?\nQui peut administrer ce traitement ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Oxygénation hyperbare", "description": "Quelles complications peuvent survenir ?\nComment gérer une embolie gazeuse ?\nQuels risques liés à l'oxygénation hyperbare ?\nComment prévenir les infections en chambre ?\nQuels signes d'une complication grave ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Oxygénation hyperbare", "description": "Quels sont les facteurs de risque de décompression ?\nQui est à risque d'intoxication à l'oxygène ?\nQuels antécédents augmentent les risques ?\nComment l'âge influence-t-il les risques ?\nQuels médicaments augmentent les risques ?", "url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une décompression ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic de décompression se fait par l'évaluation des symptômes et des antécédents d'immersion." } }, { "@type": "Question", "name": "Quels tests pour l'oxygénation hyperbare ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie et des évaluations cliniques sont utilisés pour déterminer l'indication." } }, { "@type": "Question", "name": "Quels symptômes indiquent un traitement ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des douleurs articulaires, des troubles neurologiques ou des brûlures peuvent indiquer un traitement." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité du traitement ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par l'amélioration des symptômes et des tests de suivi après traitement." } }, { "@type": "Question", "name": "Quels critères pour l'admission en chambre hyperbare ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent des conditions médicales spécifiques et l'absence de contre-indications." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'oxygénation hyperbare ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des douleurs, des vertiges, et des troubles de la vision." } }, { "@type": "Question", "name": "Comment se manifeste l'intoxication à l'oxygène ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "L'intoxication à l'oxygène se manifeste par des convulsions, des nausées et des troubles respiratoires." } }, { "@type": "Question", "name": "Quels signes d'une embolie gazeuse ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des douleurs thoraciques, des difficultés respiratoires et des troubles neurologiques." } }, { "@type": "Question", "name": "Quels symptômes après une séance d'oxygénation ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Après une séance, des sensations de fatigue ou de légers maux de tête peuvent survenir." } }, { "@type": "Question", "name": "Comment reconnaître une réaction allergique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une réaction allergique peut se manifester par des éruptions cutanées, des démangeaisons ou un gonflement." } }, { "@type": "Question", "name": "Comment prévenir la maladie de décompression ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut une ascension lente après la plongée et des pauses de sécurité." } }, { "@type": "Question", "name": "Quelles précautions avant une séance ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Évitez de fumer, de consommer de l'alcool et informez le médecin de vos antécédents médicaux." } }, { "@type": "Question", "name": "Comment éviter l'intoxication à l'oxygène ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Pour éviter l'intoxication, respectez les protocoles de traitement et les durées recommandées." } }, { "@type": "Question", "name": "Quelles sont les recommandations post-traitement ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Après traitement, reposez-vous et évitez les activités physiques intenses pendant 24 heures." } }, { "@type": "Question", "name": "Comment se préparer psychologiquement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Préparez-vous en vous informant sur le traitement et en discutant avec des professionnels." } }, { "@type": "Question", "name": "Quelles conditions traitent l'oxygénation hyperbare ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle traite des conditions comme la maladie de décompression, les infections et les brûlures." } }, { "@type": "Question", "name": "Comment se déroule une séance d'oxygénation ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Une séance se déroule dans une chambre pressurisée où le patient respire de l'oxygène pur." } }, { "@type": "Question", "name": "Quelle est la durée d'une séance ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Une séance dure généralement entre 60 et 120 minutes, selon la condition traitée." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des douleurs aux oreilles, des nausées ou des troubles visuels." } }, { "@type": "Question", "name": "Qui peut administrer ce traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement doit être administré par des professionnels de santé formés en médecine hyperbare." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des lésions pulmonaires, des convulsions et des infections." } }, { "@type": "Question", "name": "Comment gérer une embolie gazeuse ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Une embolie gazeuse nécessite une intervention rapide, souvent avec une oxygénation hyperbare." } }, { "@type": "Question", "name": "Quels risques liés à l'oxygénation hyperbare ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des barotraumatismes, des troubles de la vision et des réactions allergiques." } }, { "@type": "Question", "name": "Comment prévenir les infections en chambre ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Pour prévenir les infections, maintenez une bonne hygiène et suivez les protocoles de désinfection." } }, { "@type": "Question", "name": "Quels signes d'une complication grave ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs thoraciques intenses ou des troubles neurologiques nécessitent une attention immédiate." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de décompression ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent la profondeur de plongée, la durée et l'absence de pauses de sécurité." } }, { "@type": "Question", "name": "Qui est à risque d'intoxication à l'oxygène ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les plongeurs et les patients recevant une oxygénation hyperbare à haute pression sont à risque." } }, { "@type": "Question", "name": "Quels antécédents augmentent les risques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents de troubles respiratoires ou neurologiques peuvent augmenter les risques." } }, { "@type": "Question", "name": "Comment l'âge influence-t-il les risques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées peuvent avoir un risque accru de complications en raison de la fragilité des tissus." } }, { "@type": "Question", "name": "Quels médicaments augmentent les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments, comme les diurétiques, peuvent augmenter le risque de déshydratation et de complications." } } ] } ] }

Sources (10000 au total)

The significance of the microlymphangiogenesis, microangiogenesis, and combined detection of programmed cell death-1 protein (PD-1)/ki67 in gastric cancer tissues.

To investigate the relationship between the microlymphangiogenesis, microangiogenesis, and combined detection of the programmed cell death-1 protein (PD-1)/ki67 in patients with gastric cancer as well... Immunohistochemistry was used to detect the microlymphatic density (MLD) and microvessel density (MVD) in the central and peripheral zones in 92 cases of gastric cancer, along with the number of PD-1-... The central zone of the gastric cancer tissue contained fewer atretic cord-like lymphatic vessels than the peripheral zone, while the peripheral zone contained an increased number of lymphatic vessels... The detection of the MLD and MVD as well as the positive expression of PD-1 and ki67 in gastric cancer tissue are important reference indicators for judging the prognosis of gastric cancer....

Are programmed cell death protein-1 and Angiopoietins-2 effective biomarkers for detection the severity of psoriatic patients?

Early detection of psoriasis is still an open discussion. Psoriatic lesions are characterized by red/scaly plaques affecting different body-sites.... To evaluate the levels of programmed cell death protein-1(PD-1) and Angiopoietins-2(Ang-2) in serum, lesional, and perilesional of psoriatic patients and correlate them with controls and disease sever... Serum samples were obtained from 40 participants subdivided equally into psoriatic and healthy controls, 4 mm punch_biopsy equally from lesional and perilesional skin of individuals. PD-1/ANG-2 ELISA ... Serum and tissue levels of PD-1 and Ang-2 were overexpressed in psoriatic patients compared with controls. There was a statistical difference between patients and controls in level of PD-1(serum and t... PD-1 and ANG-2 can be highly recommended to determine the severity of psoriasis....

Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment.

Programmed cell death protein 1 (PD-1)-expressing T cells are expanded in individuals with established rheumatoid arthritis (RA). However, little is known about their functional role in the pathogenes...

A binary module for microbiota-mediated regulation of γδ17 cells, hallmarked by microbiota-driven expression of programmed cell death protein 1.

Little is known about how microbiota regulate innate-like γδ T cells or how these restrict their effector functions within mucosal barriers, where microbiota provide chronic stimulation. Here, we show...

Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma.

Esophagogastric adenocarcinoma (EGA) is one of the leading causes of cancer-related mortality worldwide. Therapeutic options are limited for patients with recurrent or metastatic disease. Targeted the... Here, a 52-year-old male patient with advanced EGA Siewert Type II shows a significant response to combination therapy with olaparib and pembrolizumab. After progression following first- and second-li... In this case, a long-lasting response to the combination of olaparib and pembrolizumab was observed despite previous treatment with a PD-L1 inhibitor. This case illustrates the need for further clinic...

An Immunochromatographic Test Strip for Rapid Quantitative Control of Monoclonal Antibodies against Programmed Cell Death Protein 1.

Cancer is one of the major public health challenges in the world, which is characterized by rapid progression and high mortality. Immunotherapy, represented by PD-1 monoclonal antibody, has significan...